Winton Group LTD Macrogenics Inc Transaction History

Winton Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$4.48 - $10.11 $68,606 - $154,824	-15,314 Reduced 48.39%	16,333 $157,000
Q3 2023 Nov 13, 2023	BUY	$4.48 - $6.19 $141,778 - $195,894	31,647 New	31,647 $147,000
Q4 2021 Feb 10, 2022	SELL	$15.91 - $21.88 $283,118 - $389,354	-17,795 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$19.74 - $28.7 $101,483 - $147,546	5,141 Added 40.63%	17,795 $373,000
Q2 2021 Aug 10, 2021	SELL	$20.49 - $35.63 $54,093 - $94,063	-2,640 Reduced 17.26%	12,654 $340,000
Q1 2021 Jul 21, 2021	SELL	$18.99 - $33.2 $18,591 - $32,502	-979 Reduced 6.02%	15,294 $487,000
Q4 2020 Feb 12, 2021	BUY	$19.41 - $26.0 $315,858 - $423,098	16,273 New	16,273 $372,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.